These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19091903)

  • 1. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
    Jacene HA; Filice R; Kasecamp W; Wahl RL
    J Nucl Med; 2009 Jan; 50(1):8-17. PubMed ID: 19091903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
    Jacene HA; Filice R; Kasecamp W; Wahl RL
    J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
    Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
    Ulaner GA; Colletti PM; Conti PS
    Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
    Torizuka T; Zasadny KR; Kison PV; Rommelfanger SG; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Jun; 41(6):999-1005. PubMed ID: 10855624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma.
    Grgic A; Nestle U; Scheidhauer K; Puskas C; Ballek E; Hohloch K; Schubert J; König J; Pinkert J; Truemper L; Hellwig D; Kirsch CM
    Nuklearmedizin; 2011; 50(1):39-47. PubMed ID: 21057722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.
    Cazaentre T; Morschhauser F; Vermandel M; Betrouni N; Prangère T; Steinling M; Huglo D
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):494-504. PubMed ID: 19820933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
    Bodet-Milin C; Touzeau C; Leux C; Sahin M; Moreau A; Maisonneuve H; Morineau N; Jardel H; Moreau P; Gallazini-Crépin C; Gries P; Gressin R; Harousseau JL; Mohty M; Moreau P; Kraeber-Bodere F; Le Gouill S
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1633-42. PubMed ID: 20428863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
    Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
    J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma.
    Goudarzi B; Jacene HA; Wahl RL
    Acad Radiol; 2010 Sep; 17(9):1175-85. PubMed ID: 20634105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early evaluation of tumor response to
    Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
    Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Hanaoka K; Hosono M; Tatsumi Y; Ishii K; Im SW; Tsuchiya N; Sakaguchi K; Matsumura I
    EJNMMI Res; 2015; 5():10. PubMed ID: 25853016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.